Indaptus Therapeutics (INDP) Financials

Indaptus Therapeutics (NASDAQ: INDP) remains a pre-revenue biotechnology company with persistent operating losses, but its Q2 2026 balance sheet improved substantially after a large equity financing. The company reported no revenue in Q2 2026 or in the comparable periods provided, while research and development activity continues to be funded primarily through equity issuances.

Q2 2026 operating expenses were $1.81 million, down from $2.16 million in Q1 2026 and well below $8.16 million in Q4 2025. The quarterly net loss narrowed to $1.79 million from $2.54 million in Q1. However, this remains a loss-making business, and the improvement appears to reflect lower expenses rather than revenue growth.

Liquidity improved sharply during the quarter. Cash and equivalents rose from $1.50 million at March 31, 2026, to $7.55 million at June 30, while the company also held $4.0 million in short-term investments. The $12.0 million common-stock issuance was the primary source of the $6.06 million increase in cash during Q2. Based on Q2 operating cash usage of $1.93 million, cash and short-term investments provide a materially stronger near-term funding position, although the actual runway will depend on clinical spending and future financing needs.

The balance sheet also became less leveraged. Total liabilities declined to $615,426 from $933,000 in Q1 2026 and $8.51 million in Q2 2025, when the company carried $6.50 million of short-term debt. Total equity was $11.37 million at the end of Q2, but retained earnings remained deeply negative at $(85.62) million, reflecting years of accumulated losses.

• Improved liquidity: Cash and short-term investments totaled approximately $11.55 million at June 30, 2026, compared with cash of $1.50 million at the prior quarter-end.
• Lower quarterly expenses: Total operating expenses fell approximately 16% sequentially to $1.81 million, with SG&A and R&D both declining from Q1.
• Narrower net loss: Q2’s $1.79 million loss improved from $2.54 million in Q1 2026 and $8.11 million in Q4 2025.
• Reduced balance-sheet risk: Total liabilities fell to $615,426, and the short-term debt reported in Q2 2025 was no longer present in the latest balance sheet.
• Lower operating cash burn: Cash used in operations improved to $1.93 million in Q2 from $7.01 million in Q1, although working-capital movements contributed to the volatility.
• Investment cash outflow appears non-operational: The $4.0 million investing outflow in Q2 corresponds with the $4.0 million short-term investment balance, suggesting a redeployment of liquidity rather than a comparable increase in research spending.
• Capital structure comparability is limited: The reported weighted-average share count changed dramatically across periods, including from 10.96 million in Q1 2026 to 116.13 million in Q2, likely reflecting financing and other capital-structure changes.
• No revenue generation: Indaptus reported zero revenue in every income statement period supplied, leaving no operating income to offset research and corporate expenses.
• Continued dependence on financing: The Q2 cash increase was driven mainly by a $12.0 million common-stock issuance, highlighting the company’s reliance on external capital to fund operations.
• Significant dilution risk and accumulated deficit: The increase in common shares can reduce existing shareholders’ ownership percentage, while retained earnings of $(85.62) million underscore the company’s long history of losses.

Investor takeaway: INDP’s latest quarter showed better liquidity, lower spending and reduced liabilities, which are constructive near-term developments. Nevertheless, the company has no revenue, continues to consume cash and funded its improved liquidity primarily through equity issuance. Investors should focus on clinical or commercial milestones, the pace of future cash burn and whether additional financing—and further dilution—will be required.